Last reviewed · How we verify
Estradiol transdermal one 90 μL spray
Estradiol transdermal one 90 μL spray is a Hormone replacement therapy (HRT) / Estrogen Small molecule drug developed by Lumara Health, Inc.. It is currently in Phase 3 development for Vasomotor symptoms associated with menopause, Moderate to severe menopausal hot flashes and night sweats.
Estradiol transdermal spray delivers the hormone estradiol through the skin to replace or supplement endogenous estrogen levels.
Estradiol transdermal spray delivers the hormone estradiol through the skin to replace or supplement endogenous estrogen levels. Used for Vasomotor symptoms associated with menopause, Moderate to severe menopausal hot flashes and night sweats.
At a glance
| Generic name | Estradiol transdermal one 90 μL spray |
|---|---|
| Sponsor | Lumara Health, Inc. |
| Drug class | Hormone replacement therapy (HRT) / Estrogen |
| Target | Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | Phase 3 |
Mechanism of action
Estradiol is a naturally occurring estrogen that binds to estrogen receptors (ERα and ERβ) throughout the body, modulating gene expression in target tissues. The transdermal spray formulation allows for continuous systemic absorption through the skin, bypassing first-pass hepatic metabolism and providing steady-state hormone levels. This mechanism is used to alleviate symptoms of estrogen deficiency and support hormonal balance in menopausal and postmenopausal women.
Approved indications
- Vasomotor symptoms associated with menopause
- Moderate to severe menopausal hot flashes and night sweats
Common side effects
- Breast tenderness
- Headache
- Nausea
- Application site reactions
- Vaginal bleeding or spotting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol transdermal one 90 μL spray CI brief — competitive landscape report
- Estradiol transdermal one 90 μL spray updates RSS · CI watch RSS
- Lumara Health, Inc. portfolio CI
Frequently asked questions about Estradiol transdermal one 90 μL spray
What is Estradiol transdermal one 90 μL spray?
How does Estradiol transdermal one 90 μL spray work?
What is Estradiol transdermal one 90 μL spray used for?
Who makes Estradiol transdermal one 90 μL spray?
What drug class is Estradiol transdermal one 90 μL spray in?
What development phase is Estradiol transdermal one 90 μL spray in?
What are the side effects of Estradiol transdermal one 90 μL spray?
What does Estradiol transdermal one 90 μL spray target?
Related
- Drug class: All Hormone replacement therapy (HRT) / Estrogen drugs
- Target: All drugs targeting Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
- Manufacturer: Lumara Health, Inc. — full pipeline
- Therapeutic area: All drugs in Endocrinology / Women's Health
- Indication: Drugs for Vasomotor symptoms associated with menopause
- Indication: Drugs for Moderate to severe menopausal hot flashes and night sweats
- Compare: Estradiol transdermal one 90 μL spray vs similar drugs
- Pricing: Estradiol transdermal one 90 μL spray cost, discount & access